Read Drug Approvals Monthly Update: June 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Get the most value and best outcomes from C&GT Cell and gene therapies (C&GTs) represent breakthrough science, but often come at a high cost. Breadcrumb Home Our solutions Condition management Cell...

Power your success with combined pharmacy and medical data Integrated data. Actionable insights. Pharmacist outreach. All in one innovative product. Breadcrumb Home Our solutions Clinical...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Read Drug Approvals Monthly Update: April 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

PUBLICATIONS FDA Decisions Expected Drug pipeline for January 2025 December 17, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

Breadcrumb Home Read, watch, listen Read Explore what's trending at Prime Example Link Example Link Card Title example Example Link Example Link Card Title example The Latest Tab 1 Press Releases...

Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

Perspectives High-Cost Therapy Profile: April Detailed information about prademagene zamikeracel Topical surgical application Date High Cost Therapy Profile Gene therapy/Dermatology Prademagene...

Read Drug Approvals Monthly Update: May 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Perspectives High-Cost Therapy Profile: May Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV) High Cost Therapy Profile Gene therapy/Hematology Fidanacogene elaparvovec-dzkt...

PUBLICATIONS FDA Decisions Expected: March 2025 Your monthly synopsis of new drugs expected to hit the market February 14, 2025 Drug pipeline for March 2025 At Prime Therapeutics (Prime), we have...

publications FDA Decisions Expected Drug pipeline for November 2024 October 14, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have...

publications High Cost Therapy Profile: November 2024 Zenocutuzumab Intravenous (IV) November 20, 2024 Oncology Proposed indications Pancreatic ductal adenocarcinoma (PDAC) and non–small...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care

Managed Healthcare Executive

Read Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

USA Today

Reuters

Insider

CNBC

Formulary Watch

Star Tribune

Business Insider

Endpoint News

PUBLICATIONS FDA Decisions Expected: June 2025 Your monthly synopsis of new drugs expected to hit the market May 21, 2025 Drug pipeline for June 2025 At Prime Therapeutics (Prime), we have...

For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

Reuters

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

Reuters

Reuters

NBC News: Patients weren't asked why they quit taking the weight loss drugs

AMCP Annual Meeting 2025 research posters Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model Click on the poster image to view the full-size version. Prime...

research 8 research posters presented by Prime at the 2024 AMCP Annual Meeting Prime remains at the forefront of researching real-world drug utilization, managed care pharmacy programs, and costs...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Breadcrumb Home Newsroom Custom Content Publications FDA Decisions Expected: October 2024 PUBLICATIONS FDA Decisions Expected: October 2024 Your monthly synopsis of new drugs expected to hit the...

publications Weight management: A holistic journey May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents...

Drug Approvals Quarterly Update: April 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

Marquee event showcased new Prime, our energy, ambition and transformative journey

Perspectives High-Cost Therapy Profile: March Detailed information about Sotatercept Subcutaneous (SC) High Cost Therapy Profile Cardiovascular Sotatercept Subcutaneous (SC) Merck/Bristol-Myers...